Einsatz von Hirudin zur Diagnostik von Gerinnungsvorgängen und Thrombin-induzierten Zellreaktionen

P. Walsmann

doi:10.1055/s-0038-1660289

Hämostaseologie, Table of Contents

Hamostaseologie 1991; 11(03): 107-113
DOI: 10.1055/s-0038-1660289

Originalarbeiten

Schattauer GmbH

Einsatz von Hirudin zur Diagnostik von Gerinnungsvorgängen und Thrombin-induzierten Zellreaktionen

P. Walsmann

¹Institut für Pharmakologie und Toxikologie der Medizinischen Akademie Erfurt

› Author Affiliations

Abstract

Zusammenfassung

Die Arbeit gibt eine Übersicht über die Verfahren zum Nachweis von Hirudin und über die Verwendung von Hirudin für die Bestimmung von Thrombin und Prothrombin. Die Möglichkeit, Hirudin zur Stabilisierung von Blutkonserven und Prothrombinkonzentraten einzusetzen, wird diskutiert.

Weiterhin wird der Einfluß von Hirudin und Hirudinfragmenten auf Thrombinvermittelte Zellreaktionen beschrieben. Insgesamt unterscheidet sich rekombinantes Hirudin in seiner Inhibitoraktivität praktisch nicht von natürlichem Hirudin, während Hirudinfragmente eine modifizierte Wirkung zeigen.

Full Text

References

LITERATUR
1 Bergmann C, Dodt J, Köhler S, Fink E, Gassen HG. Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis. Biol Chem HoppeSeyler 1986; 367: 731.
2 Bichler J, Gemmerli R, Fritz H. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb Res 1991; 61: 39.
3 Binnie CG, Erickson BW, Hermans J. Inhibitions of thrombin by synthetic hirudin peptides. FEBS-Lett 1990; 270: 85.
4 Bizios R, Lai LC, Cooper JA, Del Vechio PJ, Malik AB. Thrombin-induced adherence of neutrophils to cultured endothelial monolayers : increased endothelial adhesiveness. J Cell Physiol 1988; 134: 275.
5 Bourdon P, Maraganore JH. On the interaction of BG8865 with thrombin. Thromb Haemost 1989; 62: 533.
6 Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27: 6517.
7 Courtney M, Loison G, Lemoine Y, RiehlBellon N, Degryse E, Brown SW, Cacenave J-P, Defreyn G, Delebasse D, Bernant A, Maffrand J-P, Roitsch C. Production and evaluation of recombinant hirudin. Semin Thromb Hemost 1989; 15: 288.
8 Courtney M, Loison G, Riehl-Bellon N, Tolstoshev P, Degryse E, Marquet M, Brown S, Lemoine Y, Roitsch C. The production and evaluation of recombinant hirudin. Thromb Res 1987; VII: 30.
9 Degryse E. Determination of the specific activity of recombinant hirudin. Thromb Res 1990; 60: 433.
10 Degryse E, Acker M, Defreyn G, Bernat A, Maffrand JP, Roitsch C, Courtney M. Point mutations modifying the thrombin inhibition kinetics and antithrombic activity in vivo of recombinant hirudin. Protein Engineering 1989; 02: 459.
11 Degryse E, Ebel C. Influence of storage conditions on the activity of recombinant hirudin. Thromb Res 1991; 61: 87.
12 DeMichele MAA, Moon DG, Fenton II JW, Minnear FL. Thrombin’s enzymatic activity increases permeability of endothelial cell monolayers. J Appl Physiol 1990; 69: 1599.
13 Dietl T. Proteinasen-Inhibitoren und Proteinasen des medizinischen Blutegels: Immunologie und Gewebslokalisation, Dissertation, Universität München. 1985
14 Dodt J. Hirudine, die Thrombininhibitoren des Blutegels »Hirudo medicinalis«, Inaugural-Dissertation, Universität München. 1984
15 Dodt J, Köhler S, Baici A. Interaction of site specific hirudin variants with alphathrombin. FEBS-Lett 1988; 229: 87.
16 Dodt J, Machleidt W, Seemüller U, Maschler R, Fritz H. Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA. Biol Chem Hoppe-Seyler 1986; 367: 803.
17 Dodt J, Müller HP, Seemüller U, Chang J-Y. The complete amino acid sequence of hirudin, a thrombin-specific inhibitor. FEBS-Lett 1984; 165: 180.
18 Dodt J, Schmitz T, Schäfer T, Bergmann C. Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. FEBS-Lett 1986; 202: 373.
19 Dodt J, Seemüller U, Maschler R, Fritz H. The complete covalent structure of hirudin. Localization of the disulfide bonds. Biol Chem Hoppe-Seyler 1985; 366: 379.
20 Drawert J, Stein P. Untersuchungen zur Stabilisierung von Spenderblut mit Thrombininhibitoren. Folia Haematol 1986; 113: 560.
21 Electricwala A, Sawyer R, Atkinson T. Purification and characterization of thrombin inhibitor from novel leech species. Thromb Haemost 1989; 62: 390.
22 Fortkamp E, Rieger M, HeisterbergMoutses G, Schweizer S, Sommer R. Cloning and expression in Escherichia coli of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech. DNA 1986; 05: 511.
23 Freund M, Cazenave J-P, Courtney M, Degryse E, Roitsch C, Bernat A, Delebassee D, Defreyn G, Maffrand J-P. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats. Thromb Haemost 1990; 63: 187.
24 Friedberg RC, Hagen P-O, Pizzo SV. The role of endothelium in factor Xa regulation: the effect of plasma proteinase inhibitors and hirudin. Blood 1988; 71: 1321.
25 Gilbao N, Villanueva GB, Fenton II JW. Inhibition of fibrinolytic enzymes by thrombininhibitors. Enzyme 1988; 40: 144.
26 Glusa E, Markwardt F. Platelet functions in recombinant hirudin-anticoagulated blood. Haemostasis 1990; 20: 112.
27 Gray E, Watton J, Barrowcliffe TW, Thomas DP. Anticoagulant and antithrombic effects of recombinant hirudin. Thromb Haemost 1989; 62: 187.
28 Grießbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate. Thromb Res 1985; 37: 347.
29 Groetsch H, Damm D, Youssef RB, Haertel D. Comparison of two different methods for the determination of rDNA- hirudin in plasma samples: HPLC vs a chromogenic thrombin substrate. Thromb Res. 1991 im Druck.
30 Grossenbacher H, Auden JAL, Bill K, Liersch M, Maerki W, Maschler R. Isolation and characterization of recombinant desulfatohirudin from yeast, a highly selective thrombin inhibitor. Thromb Res Suppl 1987; VII: 34.
31 Haaland AK, Skjonsberg OH, Gravem K, Ryter R, Godai HC. Comparison of thrombin-antithrombin complex (TAT) levels and fibrinopeptide A following thrombin incubation of human plasma using hirudin, an inhibitor of TAT formation. Thromb Res 1991; 61: 253.
32 Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, Lecocq JP. Cloning and expression of a cDNA coding for the anticoagulant hirudin from bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci USA 1986; 83: 1084.
33 Hofsteenge J, Taguchi H, Stone SR. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem J 1986; 237: 243.
34 Jackson CM, Hogg PJ. Formation of a ternary complex between thrombin fibrin II monomer and heparin influences thrombin hydrolysis of chromogenic substrates and thrombin inhibition by hirudin. Thromb Haemost 1989; 62: 42.
35 Jakubowski JA. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399.
36 Jakubowski HV, Kline MD, Owen WG. The effect of bovine thrombomodulin on the specificity of bovine thrombin. J Biol Chem 1986; 261: 3876.
37 Johnson PH, Sze P, Winant R, Payne MSPW, Lazar JB. Biochemistry and genetic engineering of hirudin. Semin Thromb Hemost 1989; 15: 288.
38 Jutisz M, Martinoli G, Tertrin C. Microdosage d’une activité anti-thrombique: l’hirudine. Bull Soc Chim biol 1962; 44: 461.
39 Kisiel W, Hanahan DJ. Proteolysis of human factor II by factor Xa in the presence of hirudin. Biochem Biophys Res Commun 1974; 59: 570.
40 Klöcking H-P, Markwardt F. Influence of recombinant hirudin on the thrombogenicity of prothrombin complex concentrates. Pharmazie 1989; 44: 341.
41 Klöcking H-P, Schulze-Riewald H, Markwardt F. Inhibitory effect of hirudin on thrombosis induced by prothrombin complex concentrate. Folia Haematol 1988; 115: 106.
42 Köhler S, Dodt J. Effects of site specific amino acid exchanges in hirudin on the thrombin-hirudin interaction. Folia Haematol 1988; 115: 24.
43 Köhler M, Heiden M, Harbauer G, Miyashita C, Möhrsdorf S, Braun B, Ernert P, Wenzel E, Rose S, Pindur G. Comparison of different prothrombin complex concentrates in vitro and in vivo studies. Thromb Res 1990; 60: 63.
44 Krstenansky JL, Broersma RJ, Owen TJ, Payne MH, Yates MT, Mao SJT. Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin. Thromb Haemost 1990; 63: 208.
45 Krstenansky JL, Mao SJT. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N^a-acetyl-hirudin^45-65 . FEBS-Lett 1987; 211: 10.
46 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. Anticoagulant peptides: Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin. J Med Chem 1987; 30: 1688.
47 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. Design, synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide, hirudin. Biochim Biophys Acta 1988; 957: 53.
48 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. Comparison of hirudin and hirudin PA C-terminal fragments and related analogs as antithrombin agents. Thromb Res 1988; 52: 137.
49 Krstenansky JL, Payne MH, Owen TJ, Yates MT, Mao SJT. C-Terminal peptide alcohol, acid and amide analogs of desulfato hirudin^54-65 as antithrombin agents. Thromb Res 1989; 54: 319.
50 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464.
51 Loison G, Findeli A, Bernard M, NguyenJuilleret M, Marquet M, Riehl-Bellon N, Carvallo D, Guera-Santos L, Brown SW, Courtney M, Roitsch C, Lemoine Y. Expression and secretion in Scerevisiae of biologically active leech hirudin. Bio/Technology 1988; 06: 72.
52 Mann KG, Nesheim ME, Church WR, Haley P, Krishnawamy X. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1.
53 Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin. Identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry 1988; 27: 8170.
54 Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Preparation of antibodies to a synthetic C terminus of hirudin and identification of an antigenic site. J Immunol Meth 1989; 120: 45.
55 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JW. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095.
56 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692.
57 Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften 1955; 42: 537.
58 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. NaunynSchmiedebergs Arch Pharmacol 1956; 229: 389.
59 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seyler’s Z physiol Chem 1957; 308: 147.
60 Markwardt F. Die Bestimmung des Thrombins durch Titration mit Hirudin. Arch Pharm 1957; 290/60: 280.
61 Markwardt F. Die quantitative Bestimmung des Prothrombins durch Titration mit Hirudin. Naunyn-Schmiedebergs Arch Pharmacol 1958; 232: 487.
62 Markwardt F. Versuche zur pharmakologischen Charakterisierung des Hirudins. Naunyn-Schmiedebergs Arch Pharmacol 1958; 234: 516.
63 Markwardt F. Der Hirudintoleranztest. Klin Wochenschr 1959; 37: 1142.
64 Markwardt F, Hauptmann J, Nowak G, Kleßen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226.
65 Markwardt F, Nowak G, Stürzebecher J, Grießbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160.
66 Markwardt F, Nowak G, Stürzebecher U, Walsmann P. Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta 1987; 46: 237.
67 Markwardt F, Nowak G, Stürzebecher J, Vogel G. Clinico-pharmacological studies with recombinant hirudin. Thromb Res 1988; 52: 393.
68 Markwardt F, Stürzebecher J, Glusa E. Antithrombin effect of native and recombinant hirudins. Biomed Biochim Acta 1990; 49: 399.
69 Markwardt F, Stürzebecher J, Walsmann P. The hirudin standard. Thromb Res 1990; 59: 395.
70 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin. HoppeSeyler’s Z physiol Chem 1958; 312: 85.
71 Markwardt F, Walsmann P. Untersuchungen über den Mechanismus der Antithrombinwirkung des Heparins. HoppeSeyler’s Z physiol Chem 1959; 317: 64.
72 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombininhibitors Hirudin. Hoppe-Seyler’s Z physiol Chem 1967; 348: 1381.
73 Markwardt F, Wenzel G. Die Anwendung der Prothrombinbestimmung mit Hirudin zur Überwachung der Behandlung mit Dicumarolderivaten. Blut 1961; 40: 796.
74 Morin A, Arvier MM, Doutremepuich F, Vigneron C. Localization of the structural domain responsible for the chemotactic properties of thrombin on polymorphonuclear leucocytes. Thromb Res 1990; 60: 33.
75 Moser R, Groscurth P, Fehr J. Promotion of transendothelial neutrophil passage by human thrombin. J Cell Sci 1990; 96: 737.
76 Ofuso FA, Fenton II JW, Choay J, Hirsh J, Buchanan MR, Blajchman MA. Activation of plasma factor V by thrombin and factor Xa: Inhibition by hirudin and synthetic pentasaccharide with high affinity to antithrombin III. Thromb Haemost 1989; 62: 33.
77 Olson TA, Sonder SA, Wilner GD, Fenton II JW. Heparin binding in proximity to the catalytic site of human alpha-thrombin. Ann N Y Acad Sci USA 1986; 485: 96.
78 Owen TJ, Krstenansky JL, Yates MT, Mao SJT. N-terminal requirements of small peptide anticoagulants based on hirudin⁵⁴-⁶⁵ . J Med Chem 1988; 31: 1009.
79 Pizzo SV, Frieberg RC, Sze P, Winant R, Hudson D, Lazar JM, Johnson PH. Recombinant hirudin displaces human factor Xa from endothelial binding sites. Thromb Res 1990; 57: 803.
80 Prasa D, Stürzebecher J, Markwardt F. Hirudin als In-vitro-Antikoagulans. Pharmazie. 1991 im Druck.
81 Prescott SM, Seeger AR, Zimmerman GA, McIntyre TM, Maraganore JM. Hirudin-based peptides block the inflammatory effects of thrombin on endothelial cells. J Biol Chem 1990; 265: 9614.
82 Richter M, Walsmann P, Cyranka U, Markwardt F. ¹²⁵I-Markierung von Hirudin. Pharmazie 1986; 41: 510.
83 Richter M, Walsmann P, Markwardt F. A thrombin binding assay for ¹²⁵I-hirudin. Pharmazie 1988; 43: 369.
84 Scharf M, Engels J, Tripier D. Primary structures of new isohirudins. FEBS-Lett 1989; 255: 105.
85 Schlaeppi J-M, Vekemans S, Rink H, Chang J-Y. Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction. Eur J Biochem 1980; 188: 463.
86 Schmutzler R, Markwardt F. Der Hirudintest, eine Mikromethode zur Kontrolle des Prothrombinspiegels bei der Antikoagulanzientherapie. Klin Wochenschr 1962; 40: 796.
87 Spannagl M, Bichler J, Lill L, Schramm W, Fritz H. A fast chromogenic assay for determination of hirudin in plasma (Abstr). Thromb Haemost 1989; 62: 328.
88 Spinner S, Stöffler G, Fink E. Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. J Immunol Meth 1986; 87: 79.
89 Spinner S, Scheffauer F, Maschler R, Stöffler G. A hirudin catching ELISA for quantitating the anticoagulant in biological fluids. Thromb Res 1988; 51: 617.
90 Steiner V, Knecht R, Gruetter M. Isolation and purification of novel hirudins from leech Hirudinaria manillensis by high-performance liquid chromatography. J Chromatogr 1990; 530: 273.
91 Stölzle A. Zur perkutanen Resorption der Proteinaseninhibitoren Hirudin, Eglin und Bdellin aus dem Blutegel Hirudo medicinalis. In-vivo- und In-vitro-Studien am Meerschweinchen. Dissertation Universität München. 1982
92 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622.
93 Stone SR, Braun PJ, Hofsteenge J. Identification of regions of alpha-thrombin involved in its interaction with hirudin. Biochemistry 1987; 26: 4617.
94 Stone SR, Hofsteenge J. Effect of heparin on the interaction between thrombin and hirudin. Eur J Biochem 1987; 169: 373.
95 Stürzebecher J. Methods for determination of hirudin. Semin Thromb Hemost 1991; 17: 99.
96 Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB. Recombinant desulphatohirudin (CGP 39393). Anticoagulant and antithrombotic properties in vivo. Thromb Haemost 1989; 61: 77.
97 Talbot M. Biology of recombinant hirudin (CGP 39393). A new prospect in the treatment of thrombosis. Semin Thromb Hemost 1989; 15: 293.
98 Tripier D. Hirudin: A family of iso-proteins, isolation and sequence determination of new hirudins. Folia Haematol 1988; 115: 30.
99 Tuong A, Maftouh M, Picard C, Gachon H. Site specific radioiodination of recombinant hirudin. Anal Biochem 1990; 189: 186.
100 Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Semin Thromb Haemost 1989; 15: 316.
101 Walsmann P. Hirudin as a diagnostic agent. Folia Haematol 1988; 115: 36.
102 Walsmann P. Über den Einsatz des spezifischen Thrombininhibitors Hirudin für diagnostische und biochemische Untersuchungen. Pharmazie 1988; 43: 737.
103 Walsmann P, Vogel G. Über die Anwendung von Hirudin in klinischen Gerinnungslaboratorien. Folia Haematol 1970; 94: 143.
104 Walsmann P, Markwardt F. On the isolation of the thrombin inhibitor hirudin. Thromb Res 1985; 40: 563.
105 Weitz JI, Leslie B. Urokinase has direct catalytic activity against fibrinogen and renders it less clottable by thrombin. J Clin Invest 1990; 86: 203.
106 Yang X-J, Blajchman MA, Craven S, Smith LM, Anvari N, Ofosu FA. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-CH2C1. Biochem J 1990; 272: 399.